In sharp contrast, HMC 1 cells treated with imatinib in the presence of NGF contin ued to proliferate even after 72 h at a rate almost similar to untreated controls. In fact, NGF could sup port long term survival of these cells in the presence of imatinib. In agreement with these data NGF treatment has been shown to induce mitogenic check this signals in CD34 positive hema topoietic progenitor cells. Interestingly, it has been reported that the NGF stimulation induces the activation of Erk1 2 and PI3K, but does not induce tyrosine phos phorylation of STATs in PC12 cells, in promyeloid cell line 32D or in HMC 1 cells. On the other hand, STAT5 activation is required for the maintenance of mast cells, suggesting that NGF may induce unknown signals for the mainte nance of HMC 1 cells without STATs sig naling.
We next analyzed the gene profile induced by NGF treatment of HMC 1 cells. To understand how NGF TrkA activation counteracts the effect of c Kit inhibition and promotes survival in HMC 1 cells we performed gene expression profiling using a high density microarray technique employing the Whole Human Genome Microarray that contains 45,015 probes. First, we deter mined the genes which were regulated as a result of c Kit inhibition by comparing untreated HMC 1 cells in serum free medium with cells after addition of 5 uM imatinib for 4 h. Second, we studied changes in gene expression caused by the addition of NGF for 30 min and 2 h to the imatinib treated cells.
Based on the filtering criteria mentioned in the methods section, 524 genes of known identities were downregulated and 328 genes were upregulated by treatment with imatinib, with expression ratios ranging from 2 to 45 fold and 2 to 10 fold, respec tively. Twenty one genes of known identities were found induced after 30 min and 121 genes after 2 h of NGF sti mulation following 4 h of imatinib treatment, with fold induction values ranging from 2 to 94 and 2 to 30 fold, respectively. Furthermore, NGF treatment repressed one gene after 30 min and seven genes after 2 h in imatinib treated cells. NGF induced immediate and delayed early genes in imatinib treated HMC 1 cells including several known NGF responsive immediate early genes such as the early growth response family EGR1, 2 and 4, c FOS, and JUNB being upregulated after 30 min of NGF treatment, followed by induction of delayed early genes such as NGFI A binding protein 2, hairy and enhancer of split, Kruppel like factor 10, and activating transcription factors 3 after 2 h. Prominently, EGR1, Cilengitide first discovered as a NGF responsive gene in PC12 cells, was induced more than 90 fold within 30 min of TrkA activation providing an initial validation for our array.